This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HUSSEINI K. Manji, MD; John K. Hsiao, MD; William Z. Potter, MD, PhD
Section on Clinical Pharmacology Experimental Therapeutics Branch National Institute of Mental Health Room 2D46, Bldg 10 9000 Rockville Pike Bethesda, MD 20892

Emile D. Risby, MD
Atlanta, Ga

Arch Gen Psychiatry. 1993;50(1):73.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We read with interest the letter substantiating our finding that subchronic treatment of normal subjects with lithium is associated with enhanced release of NE. We demonstrated that 2 weeks' (but not 1 week's) lithium administration significantly increased levels of urinary NE, NMN, and a derived measure of NE release ([NE +NMN]/ [NE+NMN+VMA + MHPG], in which VMA indicates vanillylmandelic acid, and MHPG, 3-methoxy-4-hydroxyphenylglycol). Interestingly, lithium produced a nearsignificant 20% increase in levels of NE in plasma but did not affect levels of MHPG in plasma.

In their study of seven healthy volunteers, Poirier-Littre et al observe that 3-week treatment with lithium results in significant increases in levels of total DOPEG (66%) and sulfate-conjugated DOPEG (71%) in plasma. These findings are of considerable interest because Goldstein et al¹ have recently demonstrated that DOPEG in plasma (DHPG) is derived primarily from sympathetic nerves and that procedures activating the sympathetic nervous system (eg, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?